Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 2/20 | 0.39 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27261453 | 1.00 | GLP1R (0.49) | GLP1RTLR2TDP1ATMNOD1 | |
| SCHEMBL30783483 | 0.95 | TDP1 (0.43) | GLP1RTLR2TDP1ATMMEN1 | |
| SCHEMBL30783521 | 0.89 | CA1 (0.43) | TDP1ATMMEN1POLBKMT2A | |
| SCHEMBL30783494 | 0.89 | CA1 (0.43) | TDP1ATMMEN1POLBKMT2A | |
| SCHEMBL27261250 | 0.89 | GLP1R (0.41) | GLP1RTLR2TDP1ATMMEN1 | |
| SCHEMBL20450560 | 0.86 | GLP1R (0.47) | GLP1RTLR2TDP1ATMNOD1 | |
| SCHEMBL20450556 | 0.86 | GLP1R (0.47) | GLP1RTLR2TDP1ATMNOD1 | |
| SCHEMBL20450580 | 0.85 | GLP1R (0.50) | GLP1RTLR2TDP1ATMNOD1 | |
| SCHEMBL20450576 | 0.85 | GLP1R (0.50) | GLP1RTLR2TDP1ATMNOD1 | |
| SCHEMBL20450517 | 0.85 | GLP1R (0.43) | GLP1RTLR2TDP1ATMNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4561998-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | Ratio Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026072-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | CCR6, OGFRL1, IL6ST | GLP1R 3715/4885TLR2 311/4885TDP1 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.